DK0831906T3 - Behandling af T-celle-medierede autoimmune sygdomme - Google Patents

Behandling af T-celle-medierede autoimmune sygdomme

Info

Publication number
DK0831906T3
DK0831906T3 DK96921309T DK96921309T DK0831906T3 DK 0831906 T3 DK0831906 T3 DK 0831906T3 DK 96921309 T DK96921309 T DK 96921309T DK 96921309 T DK96921309 T DK 96921309T DK 0831906 T3 DK0831906 T3 DK 0831906T3
Authority
DK
Denmark
Prior art keywords
cell
treatment
mediated autoimmune
autoimmune diseases
antagonist
Prior art date
Application number
DK96921309T
Other languages
Danish (da)
English (en)
Inventor
Randolph J Noelle
Eric Claassen
Original Assignee
Tno
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno, Dartmouth College filed Critical Tno
Application granted granted Critical
Publication of DK0831906T3 publication Critical patent/DK0831906T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK96921309T 1995-06-07 1996-06-06 Behandling af T-celle-medierede autoimmune sygdomme DK0831906T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/481,735 US5833987A (en) 1995-06-07 1995-06-07 Treatment of T cell mediated autoimmune disorders
PCT/US1996/009137 WO1996040246A1 (fr) 1995-06-07 1996-06-06 Traitement de maladies autoimmunes induites par les lymphocytes t

Publications (1)

Publication Number Publication Date
DK0831906T3 true DK0831906T3 (da) 2002-05-21

Family

ID=23913182

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96921309T DK0831906T3 (da) 1995-06-07 1996-06-06 Behandling af T-celle-medierede autoimmune sygdomme

Country Status (17)

Country Link
US (4) US5833987A (fr)
EP (2) EP0831906B1 (fr)
JP (1) JPH11507058A (fr)
KR (1) KR100493482B1 (fr)
CN (2) CN1192156A (fr)
AT (1) ATE214944T1 (fr)
AU (1) AU705623B2 (fr)
CA (1) CA2223303A1 (fr)
DE (1) DE69620174T2 (fr)
DK (1) DK0831906T3 (fr)
ES (1) ES2177791T3 (fr)
HU (1) HUP9900857A3 (fr)
NO (2) NO322391B1 (fr)
NZ (1) NZ311276A (fr)
PT (1) PT831906E (fr)
WO (1) WO1996040246A1 (fr)
ZA (1) ZA964851B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (fr) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Recepteur cd40cr et ligands pour celui-ci
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
ATE356634T1 (de) * 1997-01-10 2007-04-15 Biogen Idec Inc Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
WO1999000143A1 (fr) * 1997-06-27 1999-01-07 Biogen, Inc. Therapie de blocage par cd154 pour maladies auto-immunes
EP1067954A4 (fr) * 1998-04-03 2004-08-18 Dartmouth College Utilisation d'anticorps anti-gp39 pour traiter et/ou faire regresser un lupus et une maladie renale associee
US20030077667A1 (en) * 1999-06-01 2003-04-24 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US6787318B1 (en) * 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20070160615A1 (en) * 1999-06-01 2007-07-12 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of Alzheimer's disease
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
KR20030016250A (ko) * 2000-04-25 2003-02-26 아이덱 파마슈티칼즈 코포레이션 중추신경계 림프종 치료용 리툭시맵의 초내 투여
US6797263B2 (en) 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
WO2001094586A2 (fr) * 2000-06-06 2001-12-13 Idec Pharmaceuticals Corporation Anticorps non agonistiques diriges contre gp 39 humaine, compositions les contenant et leur utilisation therapeutique
DE60305919T2 (de) * 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
AU2003284968A1 (en) * 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
SI2215119T1 (sl) * 2007-11-13 2013-04-30 Evec Inc. Monoklonska protitelesa, ki se veĹľejo na hGM-CSF, in medicinski sestavki, ki jih obsegajo
EP2229914B1 (fr) * 2009-03-20 2018-05-30 Nobel Biocare Services AG Système et procédé d'alignement des modèles virtuels
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR101614739B1 (ko) * 2015-12-01 2016-04-22 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
WO2018217918A2 (fr) 2017-05-24 2018-11-29 Als Therapy Development Institute Anticorps anti-ligand anti-cd40 thérapeutiques
WO2019175332A1 (fr) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Inhibition de la voie bh4 et utilisation de celle-ci pour traiter des maladies auto-immunes ou une hypersensibilité médiées par des lymphocytes t

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (fr) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Recepteur cd40cr et ligands pour celui-ci
US5571507A (en) * 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5958403A (en) * 1992-02-28 1999-09-28 Beth Israel Hospital Association Methods and compounds for prevention of graft rejection
AU7107794A (en) * 1993-06-10 1995-01-03 Regents Of The University Of Michigan, The Cd28 pathway immunosuppression
CN1127351C (zh) * 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders

Also Published As

Publication number Publication date
EP0831906A1 (fr) 1998-04-01
DE69620174D1 (de) 2002-05-02
US5833987A (en) 1998-11-10
CN1192156A (zh) 1998-09-02
DE69620174T2 (de) 2002-07-18
CN1827168A (zh) 2006-09-06
HUP9900857A3 (en) 1999-11-29
JPH11507058A (ja) 1999-06-22
US20040197327A1 (en) 2004-10-07
NO975520D0 (no) 1997-12-01
ATE214944T1 (de) 2002-04-15
EP0831906B1 (fr) 2002-03-27
KR19990022273A (ko) 1999-03-25
PT831906E (pt) 2002-09-30
NO975520L (no) 1998-02-06
CA2223303A1 (fr) 1996-12-19
US6328964B1 (en) 2001-12-11
AU6255996A (en) 1996-12-30
EP1161954A1 (fr) 2001-12-12
KR100493482B1 (ko) 2005-08-29
NO20045460L (no) 1998-02-06
NO322391B1 (no) 2006-10-02
ES2177791T3 (es) 2002-12-16
ZA964851B (en) 1997-07-29
NZ311276A (en) 1999-11-29
WO1996040246A1 (fr) 1996-12-19
AU705623B2 (en) 1999-05-27
US20020009450A1 (en) 2002-01-24
HUP9900857A2 (hu) 1999-07-28

Similar Documents

Publication Publication Date Title
DK0831906T3 (da) Behandling af T-celle-medierede autoimmune sygdomme
ATE524176T1 (de) Valsartan tablette
DE69527509T2 (de) Hydrogelformulierung mit gesteuerter freisetzung
KR950702550A (ko) Ampa 수용체에 의해 중재되는 시냅스 반응을 증진하는 약제(drugs that enhance synaptic responses mediated by ampa receptors)
MX9203755A (es) Dispositivo de suministro iontoforetico de drogas o agentes terapeuticos, dotado de un adhesivo de electrotransporte.
AU2002360436A1 (en) 2-aryl pyrrologpyrimidines for a1 and a3 receptors
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
NO20031018D0 (no) Oksymorfonpreparater med kontrollert frigivelse
CA2260145A1 (fr) Utilisation de l-acetylcarnitine, de l-isovalerycarnitine, de l-propionylcarnitine pour augmenter les taux de igf-1
WO2000012623A3 (fr) Utilisation
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
AU7833594A (en) Treatment of chronic anti-inflammatory diseases by angiotension II receptor antagonists
DK0966277T3 (da) Anvendelse af R-NSAID'er til forebyggelse af Alzheimer's sygdom
ES2089136T3 (es) Tratamiento de enfermedades inflamatorias con la ayuda de derivados 15-ceto-prostaglandinas.
ITRM930488A0 (it) Composizione detergente per la cura del corpo.
HU9202990D0 (en) A new application of quisqualate receptor antagonists
EE03384B1 (et) Melatoniini kasutamine ravimi tootmiseks
EE05559B1 (et) IL6R/IL6 kim„„ri kasutamine ravimi valmistamiseks, mis on ette n„htud neuroloogiliste haiguste ja h„irete ravimiseks ja/v?i v„ltimiseks
WO1998003178A3 (fr) Compositions pharmaceutiques contenant des antagonistes de recepteur purinergique p2y
DK0896822T3 (da) 4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
NO20001894L (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer
DK0454429T3 (da) Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
IT240104Y1 (it) Dispositivo per il trattamento del corpo umano.
DK0872239T3 (da) Anvendelse af olanzapin til fremstilling af et lægemiddel til behandling af cerebral fokal iskæmi